



ASX ANNOUNCEMENT

6 March 2015

## ***Director Options Vesting Condition Met***

**Melbourne, 6 March 2015:** The Board of stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), wishes to advise that the following vesting condition has been met on the unlisted 27 September 2013 \$0.40 Director Options for Dr Stewart Washer and Dr Ross Macdonald:

<b>Tranche</b>	<b>Number of Options</b>	<b>Vesting Condition</b>
B	750,000 each	The volume weighted average price of shares over a period of 10 consecutive trading days being at least \$0.80 per share.

The unlisted Director Options, which were issued on 27 September 2013, are subject to escrow until 27 November 2015.

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA technology provides a consistent, reliable source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

**CONTACTS:** Dr. Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Dr. Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)